Espinosa R, Vidal E, Jacinto B, Vázquez JP, Vázquez J, Karchmer S

Language: Spanish
References: 14
Page: 372-375
PDF size: 188.57 Kb.

ABSTRACT

This case shows the therapeutic response of levosimendan in a woman with acute heart failure secondary to postpartum cardiomyopathy. Through echocardiography she demonstrated rapid recovery of the left ventricular function and decreased brain natriuretic peptide. This is the first inotropic medication agent available from so-called calcium sensitizers with vasodilatory properties that directly influence the recovery of left ventricular function in acute heart failure.

REFERENCES

1. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971; 44 (5): 964-968.

2. Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR et al. Natural course of peripartum cardiomyopathy. Circulation. 1971; 44 (6): 1053-1061.

3. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol. 1999; 94 (2): 311-316.

4. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005; 80 (12): 1602-1606.

5. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111 (16): 2050-2055.

6. Heider AL, Kuller JA, Strauss RA, Wells SR. Peripartum cardiomyopathy: a review of the literature. Obstet Gynecol Surv. 1999; 54 (8): 526-531.

7. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD et al. Peripartum cardiomyopathy: national heart, lung, and blood institute and office of rare diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000; 283 (9): 1183-1188.

8. Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs. 2001; 10 (5): 955-970.

9. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360 (9328): 196-202.

10. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000; 102 (18): 2222-2227.

11. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg. 2004; 98 (3): 822-824.

12. Nguyen HD, McKeown B. Levosimendan for post-partum cardiomyopathy. Crit Care Resusc. 2005; 7 (2): 107-110.

13. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36 (6): 1903-1912.

14. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297 (17): 1883-1891.